Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.51 |
| ▸ | LARS1 | Q9P2J5 | 2/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | TARS1 | P26639 | 1/20 | 0.43 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL85199 | 0.81 | ALDH1A1 (0.69) | ALDH1A1NPSR1PTGS2LARS1PTGS1 | |
| SCHEMBL17286575 | 0.80 | ALDH1A1 (0.54) | ALDH1A1NPSR1PTGS2LARS1PTGS1 | |
| SCHEMBL8277097 | 0.80 | ALDH1A1 (0.72) | ALDH1A1NPSR1PTGS2PTGS1NLRP3 | |
| SCHEMBL10092605 | 0.79 | SMN1; SMN2 (0.61) | ALDH1A1PTGS2PTGS1NLRP3KDM4E | |
| SCHEMBL8277078 | 0.79 | ALDH1A1 (0.70) | ALDH1A1NPSR1PTGS2PTGS1 | |
| SCHEMBL9237237 | 0.79 | ALDH1A1 (1.00) | ALDH1A1NPSR1LARS1TARS1MEN1 | |
| SCHEMBL12339107 | 0.79 | ALDH1A1 (0.70) | ALDH1A1NPSR1PTGS2PTGS1SMN1; SMN2 | |
| SCHEMBL19627407 | 0.78 | ALDH1A1 (0.64) | ALDH1A1NPSR1 | |
| SCHEMBL17286578 | 0.78 | ALDH1A1 (0.51) | ALDH1A1NPSR1LARS1TARS1KDM4E | |
| SCHEMBL19627411 | 0.77 | ALDH1A1 (0.68) | ALDH1A1NPSR1LARS1TARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018057588-A1 | FURO[3,2-B]PYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-03-29 | — | — | WO | disclosed |
| US-20150336925-A1 | SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2015-11-26 | — | — | US | disclosed |
| US-8129410-B2 | Sleep maintenance insomnia; circadian rhythm abnormalities; side effect reduction | HYPNION, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129410-B2 | Sleep maintenance insomnia; circadian rhythm abnormalities; side effect reduction | HYPNION, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8101596-B2 | Loxapine analogs and methods of use thereof | HYPNION INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101596-B2 | Loxapine analogs and methods of use thereof | HYPNION INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8088778-B2 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-7807828-B2 | Olanzapine analogs and methods of use thereof | HYPNION, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7592333-B2 | Loxapine analogs and methods of use thereof | HYPNION, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-20090186872-A1 | LOXAPINE ANALOGS AND METHODS OF USE THEREOF | EDGAR DALE M | 2009-07-23 | — | — | US | disclosed |
| US-20090186872-A1 | LOXAPINE ANALOGS AND METHODS OF USE THEREOF | EDGAR DALE M | 2009-07-23 | — | — | US | disclosed |
| US-7563785-B2 | Quetiapine analogs and methods of use thereof | HYPNION, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20090163514-A1 | BENZISOXAZOLE PIPERAZINE COMPOUNDS AND METHODS OF USE THEREOF | COUGHLIN DANIEL | 2009-06-25 | — | — | US | disclosed |
| US-7524864-B2 | Methods of treating sleep disorders | HYPNION, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524864-B2 | Methods of treating sleep disorders | HYPNION, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7482460-B2 | Doxepin analogs and methods of use thereof | HYPNION, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482460-B2 | Doxepin analogs and methods of use thereof | HYPNION, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20080214539-A1 | Benzisoxazole Piperidine Compounds and Methods of Use Thereof | HYPNION, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080214539-A1 | Benzisoxazole Piperidine Compounds and Methods of Use Thereof | HYPNION, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20070043021-A1 | derivatives of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine for modulating sleep disorder; side effect reduction | HYPNION, INC. | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043021-A1 | derivatives of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine for modulating sleep disorder; side effect reduction | GABRB3, GRIN2C, GABRB2 | ALDH1A1 1166/4885NPSR1 86/4885PTGS2 960/4885 |
| US-20080214539-A1 | Benzisoxazole Piperidine Compounds and Methods of Use Thereof | GABRA5, GABRE, HCRTR2 | ALDH1A1 1099/4885NPSR1 348/4885PTGS2 1077/4885 |
| US-20150336925-A1 | SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCLAF1 | ALDH1A1 1179/4885NPSR1 3968/4885PTGS2 1327/4885 |
| US-20090163514-A1 | BENZISOXAZOLE PIPERAZINE COMPOUNDS AND METHODS OF USE THEREOF | GABRA5, HCRTR2, HCRTR1 | ALDH1A1 1540/4885NPSR1 205/4885PTGS2 791/4885 |
| US-20090186872-A1 | LOXAPINE ANALOGS AND METHODS OF USE THEREOF | HCRTR2, HCRTR1, HTR3B | ALDH1A1 1642/4885NPSR1 42/4885PTGS2 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.